Hardy releases telavancin susceptibility disks
Hardy Diagnostics have introduced new Telavancin 30µg, HardyDisk™ used in agar diffusion susceptibility testing methods (Kirby-Bauer).
Hardy Diagnostics is the first company worldwide to achieve 510K clearance to market this susceptibility disk. Telavancin, is a new antibiotic developed by Theravance, a California based biopharmaceutical firm. The FDA has approved telavancin injections (brand name: Vibativ) for once-daily treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant and methicillin-susceptible strains of Staphylococcus aureus.
NOTE: This item is from our 'historic' database and may contain information which is not up to date.
Source : Hardy Diagnostics View archived contact details
Posted on March 9, 2010